[1] [1] Al-Hawary MM, Kaza RK, Azar SF, et al. Mimics of pancreatic ductal adenocarcinoma[J]. Cancer Imaging, 2013, 13(3): 342-349.

[2] [2] Huang J, Lok V, Ngai CH, et al. Worldwide burden of, risk factors for, and trends in pancreatic cancer[J]. Gastroenterology, 2021, 160(3): 744-754.

[3] [3] Stoffel EM, Brand RE, Goggins M. Pancreatic cancer: changing epidemiology and new approaches to risk assessment, early detection, and prevention[J]. Gastroenterology, 2023, 164(5): 752-765.

[4] [4] Vincent A, Herman J, Schulick R, et al. Pancreatic cancer[J]. Lancet, 2011, 378(9791): 607-620.

[5] [5] Li H, Liu ZY, Wu N, et al. PARP inhibitor resistance: the underlying mechanisms and clinical implications[J]. Mol Cancer, 2020, 19(1): 107.

[6] [6] Qin C, Yang G, Yang J, et al. Metabolism of pancreatic cancer: paving the way to better anticancer strategies[J]. Mol Cancer, 2020, 19(1): 50.

[7] [7] Abrams CK. Mechanisms of diseases associated with mutation in GJC2/Connexin 47[J]. Biomolecules, 2023, 13(4): 712.

[8] [8] Winterhager E, Kidder GM. Gap junction connexins in female reproductive organs: implications for women′s reproductive health[J]. Hum Reprod Update, 2015, 21(3): 340-352.

[9] [9] Zong YJ, Liu XZ, Tu L, et al. Cytomembrane trafficking pathways of connexin 26, 30, and 43[J]. Int J Mol Sci, 2023, 24(12): 10349.

[10] [10] Srinivas M, Verselis VK, White TW. Human diseases associated with connexin mutations[J]. Biochim Biophys Acta Biomembr, 2018, 1860(1): 192-201.

[11] [11] Verselis VK, Srinivas M. Connexin channel modulators and their mechanisms of action[J]. Neuropharmacology, 2013, 75: 517-524.

[12] [12] Beyer EC, Berthoud VM. Gap junction gene and protein families: Connexins, innexins, and pannexins[J]. Biochim Biophys Acta Biomembr, 2018, 1860(1): 5-8.

[13] [13] Cigliola V, Chellakudam V, Arabieter W, etal. Connexins and -cell functions[J]. Diabetes Res Clin Pract, 2013, 99(3): 250-259.

[14] [14] Huo Y, Zhou Y, Zheng J, et al. GJB3 promotes pancreatic cancer liver metastasis by enhancing the polarization and survival of neutrophil[J]. Front Immunol, 2022, 13: 983116.

[15] [15] Zhu X, Ruan Z, Yang X, et al. Connexin 31. 1 degradation requires the Clathrin-mediated autophagy in NSCLC cell H1299[J]. J Cell Mol Med, 2015, 19(1): 257-264.

[16] [16] Ohnami S, Maruyama K, Chen K, et al. BMP4 and PHLDA1 are plausible drug-targetable candidate genes for KRAS G12A-, G12D-, and G12V-driven colorectal cancer[J]. Mol Cell Biochem, 2021, 476(9): 3469-3482.

[17] [17] Tawfik D, Zaccagnino A, Bernt A, et al. The A818-6 system as an in-vitro model for studying the role of the transportome in pancreatic cancer[J]. BMC Cancer, 2020, 20(1): 264.

[18] [18] Tiwari A, Tashiro K, Dixit A, et al. Loss of HIF1A from pancreatic cancer cells increases expression of PPP1R1B and degradation of p53 to promote invasion and metastasis[J]. Gastroenterology, 2020, 159(5): 1882-1897. e1885.

[19] [19] Aiello NM, Brabletz T, Kang Y, et al. Upholding a role for EMT in pancreatic cancer metastasis[J]. Nature, 2017, 547(7661): E7-E8.

[20] [20] Ozcivici E, Mese G. Comprehensive analysis of GJB1 in breast cancer: its implications in survival and molecular mechanisms[J]. Anticancer Res, 2024, 44(12): 5379-5391.

[21] [21] Sherman MH, Beatty GL. Tumor microenvironment in pancreatic cancer pathogenesis and therapeutic resistance[J]. Annu Rev Pathol, 2023, 18: 123-148.

[22] [22] Jia Y, Guo B, Zhang W, et al. Pan-cancer analysis of the prognostic and immunological role of GJB2: a potential target for survival and immunotherapy[J]. Front Oncol, 2023, 13: 1110207.

[23] [23] Yang J, Qin G, Luo M, et al. Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT[J]. Cell Death Dis, 2015, 6(7): e1829.

[24] [24] Qin H, Zheng B, Lin Z, et al. Ibrutinib contributes to atrial arrhythmia through the autophagic degradation of connexins by inhibiting the PI3K-AKT-mTOR signaling pathway[J]. Front Biosci(Landmark Ed), 2024, 29(5): 201.

[25] [25] Davis HM, Pacheco-Costa R, Atkinson EG, et al. Disruption of the Cx43/miR21 pathway leads to osteocyte apoptosis and increased osteoclastogenesis with aging[J]. Aging Cell, 2017, 16(3): 551-563.

[26] [26] Xia Y, Zhang S, Luo H, et al. Repositioning of Montelukast to inhibit proliferation of mutated KRAS pancreatic cancer through a novel mechanism that interfere the binding between KRAS and GTP/GDP[J]. Eur J Pharmacol, 2023, 961: 176157.

[27] [27] Gil da Costa RM, Medeiros R. Bovine papillomavirus: opening new trends for comparative pathology[J]. Arch Virol, 2014, 159(2): 191-198.